Default company panoramic image
Logo

Domainex Ltd

Domainex whose first project will be out-licensed in 2013 and will generate value over next 3 years by trade sale or sale of projects.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP
  • Founded January 2001
  • Employees 35
  • Website domainex.co.uk

Company Summary

Domainex has two business units. A service business that generates revenues and a drug discovery unit that has programmes around kinases for oncology and epigenetics. Domainex's pipeline is unique in focussing upon challenging and novel targets which is now reaching a stage were we anticipate a first out-licensing deal which will generate value for the company during 2013.

Team

  • Default avatar
    Eddy Littler
    Dr

    Eddy has worked in senior roles for 23 years in Pharma and Biotech with Wellcome, GSK and Medivir. In his time at Medivir he played a major role in the development and out-licensing of a hepatitis C drug to J&J.
    At Domainex he has raised over £3m from angel and corporate investors and has led the company to generate over £15m in revenues.

  • Default avatar
    Trevor Perrior
    Dr

    Trevor has spent over 20 years in pharma and biotech with ICI, Astrazeneca and Celltech. He has taken 10 drugs into the clinic with one marketed drug

Advisors

  • Default avatar
    Charles Waddell
    Lawyer
    Unconfirmed
    Default avatar
    Anthony Signorini
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Longbow Capital, Bury Fitzwilliam-Lay, UCLB, Takeda Ventures
    Unconfirmed
    Default avatar
    Capital Fund, BBSF
    Unconfirmed